Stroke has characterized cardioembolic stroke as an important clinical entity, because it is the most common cause of death in cases of acute ischemic stroke. [1] [2] [3] Transesophageal echocardiography (TEE) is accepted as a crucial investigation for detecting the thromboembolic source and determining stroke subtype. However, it is sometimes difficult to make a diagnosis because of the splashing and vanishing of the intracardiac source of the emboli. [4] [5] [6] [7] [8] [9] [10] [11] [12] In patients with cardioembolic stroke it is necessary to carefully examine the intracardiac hypercoagulable state based on echocardiographic findings and/or serum sensitive markers, and then use this information to prevent recurrent attacks.
reduction in LAA emptying flow velocity. 6, 10, 12, 13 Serum fibrin monomer (FM) is a precursor of the fibrin polymer that is produced by the thrombin-mediated resolution of fibrinopeptide A from fibrinogen. In vivo, compared with fibrin polymer and stable fibrin, FM is fragile as a result of fibrinolysis. Therefore, it is thought to be a sensitive marker of a hypercoagulable state. 14, 15 It has been reported that the measurement of serum FM level is a useful screening tool for identifying older individuals at increased risk of ischemic stroke. 16, 17 The goal of this study was to investigate the association of serum FM level with LAA flow pattern alteration and thrombus formation in order to establish whether the serum level of FM is a sensitive screening tool for diagnosing stroke subtypes in the acute stroke care unit.
clinical categories of ischemic stroke (Oxfordshire Community Stroke Project classification) 18, 19 and disease severity using the National Institute of Health Stroke Scale (NIHSS). 20 All patients underwent cerebral computed tomography and/or magnetic resonance imaging on admission, continuous electrocardiographic (ECG) monitoring to determine their cardiac rhythms, and were treated on a standardized protocol for the management of dehydration, hyperglycemia, hypoxia, and pyrexia. We classified study subjects into 2 groups based on the presence of thrombus formation in the LAA (Group P: cases with LAA thrombus, n=24, age 71±12 years old; Group N: no thrombus, n=180, 70±10 years), and compared the serum coagulation and fibrinolytic activity of the 2 groups. The local ethics committee approved the study protocol, and informed consent was given by all subjects.
Echocardiography
Transthoracic echocardiography was performed using an ultrasound instrument (Hewlett Packard SONOS 7500) equipped with a sector transducer (carrier frequency of 2.5 or 3.75 MHz). A 5-MHz phased-array multiplane probe was used for TEE. We examined the following parameters and findings using standard views and techniques: left atrial dimension; left ventricular end-diastolic dimension; left ventricular percent fractional shortening; left ventricular mass index; the ratio of peak early to late ventricular diastolic filling velocity; the deceleration time of the early diastolic filling wave; and the presence of an atrial septal aneurysm, a patent foramen ovale, spontaneous echographic contrast, or LAA thrombus. [21] [22] [23] 
Indices of LAA Function
The LAA emptying flow velocity at atrial systole (LAA eV) was assessed by pulsed-wave Doppler with the sample volume placed 1 cm distal from the mouth of the LAA; the maximum velocity was obtained by scanning the appendage at angles from 0°to 90°. 24 LAA flow velocity profiles were classified into 5 types: (I) sinus rhythm with early diastolic small wave (e) corresponding to mitral valve opening and followed by a larger wave, immediately after the ECG P wave, corresponding to LAA contraction; (II) sinus rhythm with no e wave; (III) atrial fibrillation (AF) with serrate and multiphasic waves at velocities larger than the e wave velocity; (IV) AF with fibrillatory waves at velocities lower than the e wave velocity; (V) AF with a prolonged very low-velocity signal without an e wave. 24 All measurements were determined as the mean of 5 consecutive cardiac cycles.
Hemostatic Markers
Blood samples were taken to determine the levels of hemostatic markers at the time of the echocardiographic studies and were stored at -80°C until processing. We assessed antithrombin III (AT III), thrombin -antithrombin complex (TAT), fibrinogen, and FM as indices for coagulation; plasminogen, plasmin activator inhibitor-1 (PAI-1), 2-plasmin inhibitor ( 2-PI), and plasmin-2-PI complex (PIC) as indices for fibrinolysis; and fibrinogen degradation products (FDP) and D-dimer as resolving products for fibrinogen and stable fibrin. General biochemical parameters were measured by routine laboratory methods. Normal upper limits (or ranges) for these markers in our laboratory were as follows: AT III 75-125%, TAT <3.0 ng/ml, fibrinogen 150-400 mg/dl, plasminogen 75-125%, PAI-1 <50 ng/ml, 2-PI 75-125%, PIC <0.8 g/ml, FDP <5.9 g/ml, and Ddimer 0.1-1.0 g/ml. Serum FM levels were measured by an enzyme-linked immunosorbent assay as reported previously, and normal upper limit was 6.1 g/ml. 25 
Statistical Analysis
Results are expressed as mean ± standard deviation values for continuous variables and as the percentage of total patients for categorical variables. Statistical analysis was conducted using Stat View 5.0 for Macintosh (Abacus Concepts, Inc, CA, USA). Patient characteristics, echocardiographic parameters, and hemostatic markers between patients in Group P and N were compared using the MannWhitney U-test for continuous and the chi-square test for categorical variables. FM levels between cases with and without thromboembolic risk factors (AF, hypertension, diabetes mellitus, having past history of ischemic stroke, spontaneous echographic contrast, and LAA flow pattern type IV or V) were also compared using the Mann-Whitney U-test. Comparisons of echocardiographic parameters and hemostatic markers according to LAA flow patterns in patients with Group N were determined using the KruskalWallis test. P values of less than 0.05 were considered significant. Multivariate logistic regression analysis was performed to determine independent predictors of LAA thrombus in hemostatic variables with a univariate p-value <0.05. Risk ratios are shown with 95% confidence intervals (CI). 
Results

Patient's Characteristics
There were no significant differences between the 2 groups in age, sex distribution, prevalence of hypertension, diabetes mellitus, hyperlipidemia, and history of atherothrombotic diseases, NIHSS, distribution of clinical stroke categories, or medication with antiplatelet agents before the admission. However, the incidence of chronic or paroxysmal AF was significantly higher in Group P than in Group N (75% vs 35%, p=0.001) ( Table 1) .
Echocardiographic Parameters
There were no significant differences between the 2 groups in left ventricular end-diastolic dimension, systolic fractional shortening, mass index, intima -media thickness in the aortic arch, prevalence of atrial septal aneurysm or patent foramen ovale. Group P had a significantly larger left atrial dimension, smaller LAA eV, and higher prevalence of spontaneous echographic contrast than did Group N (Left atrial dimension, 48±8 vs 41±7 mm, p=0.0002; LAA eV, 0.23±0.15 vs 0.52±0.26 m/s, p<0.0001; spontaneous echographic contrast, 67% vs 22%, p<0.0001) ( Table 2) . Table 3 .
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Hemostatic Findings Serum levels of TAT, FM, PAI-1, PIC, D-dimer, and FDP were markedly higher in Group P than in Group N (TAT, 21±23 vs 11±16 ng/ml, p=0.0105; FM, 88±52 vs 14± 9 g/ml, p<0.0001; PAI-1, 22±13 vs 14±8 ng/ml, p=0.0060; PIC, 2.8±4.0 vs 1.2±1.0 ng/ml, p=0.0042; D-dimer, 7.5±4.9 vs 1.7±2.3 g/ml, p=0.0056; FDP, 11.1±1.7 vs 2.8±1.8 g/ml, p=0.0010) (Table 3, Fig 1a) . On multivariate logistic regression analysis, the FM level was an independent predictor for LAA thrombus (risk ratio 2.975 per 10 g/ml increase; 95% CI 1.114-4.820, p=0.0214) ( Table 4) .
Serum FM Level and LAA eV According to Thromboembolic Risk Factors
In Group N, cases of LAA flow pattern type IV or V, but not with hypertension, diabetes mellitus, past history of ischemic stroke or spontaneous echocardiographic contrast, had significantly higher FM levels than in those with type I, II or III pattern (LAA flow pattern IV or V, 42±12 vs I, II, or III, 8±5 g/ml, p<0.0001). Cases of AF had higher levels of FM and smaller LAA eV than those in Group N with sinus rhythm only (Group P: FM, 85±45 vs 95±73 g/ml, NS; LAA eV, 0.21±0.14 vs 0.30±0.17 m/s, NS) (Group N: FM, 24±10 vs 9±5 g/ml, p=0.0211; LAA eV, 0.36±0.18 vs 0.57±0.22 m/s, p=0.0301) (Table 5) . FM, but not LAA eV, was significantly higher in cases of sinus rhythm in Group P than in those with AF in Group N (FM, 95±73 vs 24± 10 g/ml, p<0.0001; LAA eV, 0.30±0.17 vs 0.36±0.18 m/s, NS).
Comparison of FM With LAA Flow Pattern
There were significantly more patients with LAA thrombus in the types IV and V LAA flow pattern groups than in other 3 types (type I, 0%; II, 13%; III 6% vs IV, 30% and V, 50%, p=0.002). In the LAA thrombus negative group, cases of type IV or V flow patterns had significantly higher FM levels than the other 3 types (type I, 8.3±6.2; II, 10.2± 3.8; III, 5.4±2.4 vs IV, 39.5±11.8 and V, 53.7±14.1 g/ml, p<0.05). There were no significant differences in left atrial dimension and other hemostatic markers among the 3 groups with AF (Table 6, Fig 1b) .
Discussion
TEE is a widely accepted tool for identifying intracardiac embolic sources and for diagnosing cardioembolic stroke in the stroke care unit. On TEE, a reduction in the LAA eV or the development of spontaneous echocardiographic contrast reflects atrial mechanical remodeling and thrombus formation. 26, 27 On the other hand, TEE is a semi-invasive examination that is not easy to do frequently to follow changes in intracardiac thrombus formation and thus help to prevent recurrent attacks. FM is a precursor of a fibrin polymer that is produced by the thrombin-mediated resolution of fibrinopeptide A from fibrinogen, which has been found to be a sensitive in vivo marker for the hypercoagulable state. [14] [15] [16] [17] However, the clinical significance of the FM level in the acute period in helping to determine stroke subtype has not yet been clearly shown. In this study, we investigated the serum FM levels of patients with acute ischemic stroke and compared them with alterations in LAA flow patterns in order to establish whether the serum FM level is a sensitive predictor for the LAA hypercoagulable state and thrombus formation. In our study, LAA thrombus cases had higher FM levels and smaller LAA emptying flow velocity than those without LAA thrombus. Of note, 75% of LAA thrombus cases were complicated by AF. These results suggested that AFmediated LAA mechanical remodeling is reflected in FM level, left atrial dimension, and LAA eV, and is not related cardioembolic stroke liability.
It has been reported that, during the acute period, patients with cardioembolic stroke lose the systemic balance between coagulability and fibrinolytic activity. 27 Thus, plasma concentrations of TAT and D-dimer are useful indicators of patients who are prone to recurrent embolization. 28, 29 In the present study, to prove a direct relationship between serum FM level and LAA thrombus occurrence, we performed a multivariate logistic regression analysis of data from more than 200 patients with cerebral infarction, which clearly showed that serum FM level was an independent predictor for LAA thrombus, as compared with TAT, PAI-1, PIC, Ddimer, FDP, and the NIHSS score, which reflect the severity of cerebral infarction.
Fatkin et al classified LAA flow characteristics into 2 patterns in sinus rhythm and 3 in AF. 23 According to their report, the type V flow pattern, which was characterized as a prolonged very-low velocity signal at atrial systole with no early diastolic emptying wave, directly contributed to LAA thrombus formation. On the other hand, there are some published cases in which an intracardiac source of emboli could not be identified, and the cause of the cerebral infarction was missed. 30, 31 In the present patients, LAA thrombus was not present in 50% of cases with a type V flow pattern and in 70% of cases with a type IV flow pattern. Therefore, to clarify the direct contribution of the LAA flow pattern and the FM level, we analyzed serum coagulation markers only in patients with no LAA thrombus. We found that the serum FM level was significantly higher in cases of LAA flow pattern types IV and V than in those with the other 3 types (including cases of type III in AF). Furthermore, despite the comparable and smaller levels of LAA eV, FM was significantly higher in cases of sinus rhythm and LAA thrombus positive than in those with AF and thrombus negative. Serum FM levels were not affected by cardiac rhythm and the other thromboembolic risk factors, such as hypertension, diabetes mellitus, past history of ischemic stroke, and spontaneous echocardiographic contrast.
Our present study clearly shows that assessing the serum FM level, as well as identifying intracardiac sources of emboli in the stroke care unit, might be useful in determining stroke subtype and in deciding on long-term treatment strategies as compared with the LAA flow pattern analysis and other serum coagulation and fibrinolytic markers.
Study Limitations
First, the number of subjects in the LAA thrombus positive group was small. Second, we could not examine serum FM levels in patients treated with anticoagulants, which effectively suppress the serum levels of coagulation markers. 32 Third, we did not examine the presence of venous thrombosis, which might contributed to the increased serum FM level. Finally, we did not examine long-term mortality and recurrence in all recruited patients. Further study is needed to prove the close association of higher FM level and/or LAA flow pattern alteration with long-term prognosis.
Conclusion
Our study found that it may be possible to identify individuals at increased risk of cardioembolic stroke based on serum coagulation markers and the LAA flow pattern, especially in AF patients. The serum FM level may be a sensitive indicator for the occurrence of LAA thrombus formation and hypercoagulable state in patients with acute ischemic stroke.
